CTSO
CytoSorbentsANasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-03
Current thesis
The best near-term upside path is a credible May 13, 2026 Q1 report that shows lower cash burn, stable core revenue, and clearer FDA resubmission timing for DrugSorb-ATR, which could help the market look through current distress signals.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
CTSO must regain Nasdaq minimum bid-price compliance by September 28, 2026 or face continued reverse-split or delisting risk [#8-K-2026-04-02].
Momentum
79
Value
36
Sentiment
75
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.75 · Bull $1.20 · Bear $0.35
Data freshness
Prices
As of 2026-06-03
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-03 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-03
Investment thesis
As of 2026-06-03
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $5.38
Why
Momentum79 · Δ7d -
Value36 · Δ7d -0.0
Sentiment75 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
79
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
36
32% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
75
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 78.8 / Value 36.3 / Sentiment 74.7
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$30.14M
Beta
1.39
Shares Out
62.8M
P/E (TTM) · Derived
-1.3
P/S (TTM)
1.22
P/FCF (TTM) · Derived
-2.90
Rev YoY
+10.1%
EPS YoY
+0.6%
Gross Margin
+77.0%
Op Margin
-41.9%
Net Debt
$10.72M
Current Ratio
2.11
As of 2026-06-03 • Updated nightlySource: Internal modelMethodology